Associations between polymyalgia rheumatica and giant cell arteritis and twelve cardiovascular diseases by Pujades Rodriguez, M et al.
ORIGINAL ARTICLE
Associations between polymyalgia rheumatica and
giant cell arteritis and 12 cardiovascular diseases
Mar Pujades-Rodriguez,1,2 Bram Duyx,1 Sara L Thomas,3 Dimitris Stogiannis,1
Liam Smeeth,1,3 Harry Hemingway1
▸ Additional material is
published online only. To view,
please visit the journal online
(http://dx.doi.org/10.1136/
heartjnl-2015-308514).
1Clinical Epidemiology Group,
Farr Institute of Health
Informatics Research, University
College London, London, UK
2Leeds Institute of Biomedical
& Clinical Sciences,
MRC Medical Bioinformatics
Centre, University of Leeds,
Leeds, UK
3Faculty of Epidemiology and
Population Health, London
School of Hygiene and Tropical
Medicine, London, UK
Correspondence to
Dr Mar Pujades Rodriguez,
MRC Medical Bioinformatics
Centre, University of Leeds.
Worsley Building, Clarendon
Way, Leeds LS2 9NL;
M.D.M.PujadesRodriguez@
leeds.ac.uk
Received 7 August 2015
Revised 13 November 2015
Accepted 27 November 2015
Published Online First
19 January 2016
▸ http://dx.doi.org/10.1136/
heartjnl-2015-308926
To cite: Pujades-
Rodriguez M, Duyx B,
Thomas SL, et al. Heart
2016;102:383–389.
ABSTRACT
Objectives Evidence of the association of polymyalgia
rheumatica (PMR) and giant cell arteritis (GCA) with the
full range of cardiovascular diseases (CVDs) is limited.
We examined their relationship with the ﬁrst clinical
presentation of the 12 most common CVDs in an
unselected population-based cohort of men and women.
Methods We analysed CArdiovascular disease research
using LInked Bespoke studies and Electronic health
Records (CALIBER) data, which links primary care and
hospital and mortality data in England, from 1997 to
2010. We assembled a cohort of men and women
initially free from CVD at baseline and included all
patients with PMR and/or GCA (PMR/GCA) diagnosis,
matched by age, sex and general practice with up to 10
individuals without PMR/GCA. Random effects Poisson
regression analysis was used to study the association
between PMR/GCA and the initial presentation of 12
types of CVDs.
Results The analysis included 9776 patients with PMR
only, 1164 with GCA only, 627 with PMR and GCA and
105 504 without either condition. During a median of
3.14 years of follow-up 2787 (24.1%) individuals with
PMR/GCA and 21 559 (20.4%) without PMR/GCA
developed CVDs. Patients with PMR/GCA had lower
rates of unheralded coronary death (3.18 vs 3.61/1000
person-years; adjusted incidence ratio 0.79, 95% CI
0.66 to 0.95), transient ischaemic attack (5.11 vs 5.61/
1000 person-years; 0.67, 95% CI 0.54 to 0.84) and
coronary and death composite (24.17 vs 25.80/1000
person-years; 0.90, 95% CI 0.82 to 0.98). No
associations were observed for other CVDs or
cerebrovascular diseases, and in patients with only PMR
or GCA. No evidence of interaction by age or sex was
found. Estimates decreased with longer PMR/GCA
duration and ﬁndings were robust to multiple sensitivity
analyses.
Conclusions In this large contemporary population-
based cohort the presence of PMR and/or GCA was not
associated with an increased risk of CVDs or
cerebrovascular diseases regardless of PMR/GCA
duration.
INTRODUCTION
Polymyalgia rheumatica (PMR) and giant cell arter-
itis (GCA) are two chronic inﬂammatory diseases
with similar genetic and acute-phase response pat-
terns that affect predominantly women aged
≥50 years.1 2 These diseases are associated with
high ﬁnancial burden related to development of
complications, and the number of incident cases is
predicted to increase as a result of population
aging.3
The inﬂammatory nature of the two conditions
and presence of clinical or subclinical arteritis4–6
might lead to an increased risk of cardiovascular
diseases (CVDs). Findings from the few available
studies investigating the association between PMR
and/or GCA and CVDs are heterogeneous and con-
ﬂicting,7 with some reporting increased risk and
others reporting an absence of association.8 9 A
recent meta-analysis including six observational
studies did not ﬁnd evidence of increased risk of
coronary artery disease in patients with GCA com-
pared with non-GCA.9 Most existing studies were
conducted in tertiary or secondary care centres,
two unpublished studies contributed half of the
patients included and most did not adjust for major
cardiovascular factors (eg, smoking, blood pressure
and/or diabetes). Two large studies analysed
primary care records in the UK8 10 and found an
increased risk of peripheral arterial disease (PAD)
and of composite endpoints of coronary and cere-
brovascular diseases in patients with PMR8 or
GCA.10 However data were not linked to the mor-
tality register or hospital records and covered a
very large time span (1987–1999 and 1990–2010)
in which diagnosis practice and clinical manage-
ment for cardiovascular and chronic inﬂammatory
conditions have considerably evolved. Estimates
reported by Tomasson were unadjusted for cardio-
vascular factors. Furthermore, the study by
Hancock excluded patients with another inﬂamma-
tory rheumatoid disease and patients without
smoking information (in adjusted analysis) and deﬁ-
nitions of confounders are not available.
Because one in two patients diagnosed with GCA
will also develop PMR11 and the two diseases are
closely related, most published research has
included a large proportion of individuals with the
two conditions and/or reported combined analyses.
However, the strength of the associations with dif-
ferent presentations of CVD might vary for each of
the two conditions, and it is important to also
assess them separately.
In this longitudinal population-based study of
individuals registered in primary healthcare prac-
tices with linked information to hospital, registry
and mortality data, we examine the association
between PMR and GCA and the 12 most common
clinical initial presentations of CVD. We also assess
whether associations differ according to disease
duration, sex, age or presence of other autoimmune
diseases.
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METHODS
Study population
All patients with prospectively recorded PMR and/or GCA diag-
nosis between January 1997 and March 2010 were identiﬁed in
the CALIBER (CArdiovascular disease research using LInked
Bespoke studies and Electronic health Records) dataset.12 This
dataset links 225 primary care practices in England to hospital
and mortality data, and the validity of both risk factor and
disease records is supported by results from previous cardiovas-
cular studies.13–16
For each patient with PMR/GCA, up to 10 individuals
matched on age (±5 years), sex and practice were randomly
selected among those who, on their matched inclusion date, had
contacted the medical practice within 1 year and had not been
diagnosed with the disease (concurrent sampling). At the start
of the observation period all patients were ≥18 years old, free
of prior CVD and had been registered with their practice for
≥1 year.
PMR and GCA
Patients with recorded diagnosis of PMR and/or GCA were
identiﬁed from electronic medical records using Read and
ICD-10 codes (see online supplementary table S1). Those with
supporting information for PMR or GCA diagnosis (recorded
diagnosis in both primary care and hospital; ≥2 corticosteroid
prescriptions, ≥1 immunosuppressant drug prescription (see
online supplementary table S2) or under the care of a rheuma-
tologist within 6 months) were included in primary analyses (see
online supplementary ﬁgure S1 and table S3). Patients without
supporting information for diagnosis were included in sensitiv-
ity analyses. Individuals were initially categorised as having
PMR and/or GCA (PMR/GCA group) or not having either con-
dition. Because it is uncertain whether the two conditions are
different presentations of the same disease, they were then
divided into subgroups of those diagnosed only with PMR, only
with GCA or with GCA regardless of previous or later PMR
diagnosis during follow-up (all GCA). Patients were further clas-
siﬁed into incident and prevalent cases, depending on whether
the ﬁrst recorded diagnosis was made before or after/on study
entry.
Covariates
Baseline covariates considered were: sociodemographic (sex, age
and index of multiple deprivation), cardiovascular (diabetes
diagnosis, smoking status, body mass index, systolic blood pres-
sure, and total and high-density lipoprotein cholesterol), ≥2
prescriptions in the past year (blood pressure lowering drugs,
statins, non-steroidal anti-inﬂammatory drugs (NSAIDs),
immunosuppressant drug, oestrogen oral contraceptives and
hormone replacement therapy), diagnosis with another auto-
immune diseases (see online supplementary table S4) and year
of study entry. As in previous CALIBER analyses,13–17 physician
diagnoses recorded before or on the entry date were used and
the biomarker (eg, blood pressure) measures and smoking status
most recently recorded in Clinical Practice Research Datalink
(CPRD) up to 1 year before the entry date were used to deﬁne
baseline covariates. Deﬁnitions can be found at https://www.
caliberresearch.org/portal/.
Endpoints
The primary study endpoints were the initial presentation of 12
fatal and non-fatal cardiac and arterial vascular diseases of het-
erogeneous pathophysiology identiﬁed across the four linked
data sources in CALIBER: the CPRD18; the Myocardial
Ischaemia National Audit Project disease registry19; Hospital
Episodes Statistics; and the national death registry. CVD presen-
tations studied were: coronary diseases (stable angina, unstable
angina, myocardial infarction and unheralded coronary death),
cardiac diseases (heart failure and cardiac arrest), cerebrovascu-
lar diseases (transient ischaemic attack (TIA), ischaemic stroke,
subarachnoid haemorrhage and intracerebral haemorrhage),
PAD and abdominal aortic aneurysm. Secondary endpoints were
two composite outcomes, coronary and CVD death (including
myocardial infarction, stable angina, coronary heart diseases not
otherwise speciﬁed and cardiovascular death); and fatal and
non-fatal CVD (additionally including TIA, PAD, non-fatal
ischaemic or haemorrhagic stroke and heart failure); and ﬁrst
event of each CVD type (ie, regardless of other earlier CVD
presentations during follow-up). Diagnosis codes can be found
at http://www.caliberresearch.org/portal/.
Study follow-up period
For individuals with PMR/GCA the observation period began
on the date on which the patient fulﬁlled all the study inclusion
criteria, or the date of ﬁrst recorded diagnosis for patients with
incident PMR/GCA (see online supplementary ﬁgure S2). For
individuals without PMR/GCA, it started on the entry date of
the matched individual with PMR/GCA. For all patients the
study ended on the date of cardiovascular endpoint diagnosis,
death, practice deregistration, last practice data collection date
or diagnosis of PMR/GCA (for patients who contributed
follow-up to both the PMR/GCA and non-PMR/GCA groups).
Statistical analysis
Incidence rates of events per 1000 person-years of follow-up
with 95% CIs were calculated in patients with and without
PMR/GCA, separately for individuals with prevalent or incident
PMR/GCA, and for patients exclusively diagnosed with PMR or
GCA. Associations between PMR/GCA and every study end-
point were assessed with random effects Poisson regression
accounting for clustering between practices. Missing values of
covariates were multiply imputed (see online supplementary
text S1). Models were initially adjusted for age and sex, then
additionally for cardiovascular factors. To explore possible path-
ways or mediators of any increase in risk, estimates were further
adjusted for: (i) lipid and blood pressure lowering medication;
(ii) diagnosis of another autoimmune disease; and (iii) anti-
inﬂammatory and/or immunosuppressant drugs.
In secondary analyses: (i) evidence of interactions with sex
and age were assessed using Wald tests for interaction; (ii) the
relationships with prevalent and incident PMR/GCA were
studied; (iii) associations were assessed separately for patients
who had only one of the two diseases and for those who had
GCA regardless of PMR diagnosis. Furthermore, to examine the
association between disease duration and CVD, the follow-up of
patients with incident PMR/GCA was split into duration periods
(0–1, 2–4 and ≥5 years). Patients with prevalent disease who
had a ﬁrst diagnosis recorded ≥5 years before study entry were
included in the ≥5 year period group. Those with prevalent
disease of shorter duration (<5 years) were excluded from this
analysis because of uncertainty about exact disease duration.
Sensitivity analyses comprised: (i) exclusion of patients with
another autoimmune disease; (ii) restriction to patients with
≥6 months of follow-up; and (iii) exclusion of 2 years of
follow-up prior to PMR/GCA diagnosis for patients who con-
tributed to the exposed and unexposed groups (to account for
delays in diagnosis); (iv) inclusion of patients without support-
ing information for PMR/GCA diagnosis; (v) exclusion of
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patients of <50 years of age; (vi) inclusion of ﬁrst cardiovascu-
lar events irrespective of other earlier CVD presentations; (vii)
comparison of estimates in the periods before and after the
introduction of the pay for performance scheme in England
(Quality of Outcomes Framework); and (viii) restriction to
patients with evidence of active disease (baseline c-reactive
protein (CRP) >3.0 mg/mL or elevated erythrocyte sedimenta-
tion rate (ESR)).
Statistical analyses were done with Stata (V.13.1).
Ethical considerations
Approval was granted by the Independent Scientiﬁc Advisory
Committee of the Medicines and Healthcare Products
Regulatory Agency and the MINAP Academic Group. We regis-
tered the protocol at clinicaltrials.gov (NCT02062021).
RESULTS
Baseline patient characteristics
In total 11 567 patients with PMR/GCA and supporting diagno-
sis information and 105 504 non-PMR/GCA patients free of
CVD were identiﬁed (ﬁgure 1). Of patients with PMR/GCA,
9776 (84.5%) had only PMR, 1164 (10.1%) only GCA and 627
(5.4%) were diagnosed with both PMR and GCA. A total of
1848 contributed follow-up time to both the PMR/GCA and
non-PMR/GCA cohorts (see online supplementary ﬁgure S2).
Of the 11 567 patients with PMR/GCA, 8238 (71.2%) had inci-
dent disease, and of the 3329 patients with prevalent disease,
26.4% had been diagnosed ≥5 years before study entry. Overall,
median duration since practice registration was 13.5 years (IQR
6.1–25.5). Baseline median age was 70 years (IQR 63–77), and
72.3% of patients were women (see table 1 and online supple-
mentary table S5). Patients contributed 473 029 person-years of
follow-up, median of 3.13 years (IQR 1.3–6.0). In the year
before entry 48.1% of PMR/GCA patients had received ≥2 pre-
scriptions of oral corticosteroids (36.5% of incident and 77.0%
of prevalent cases), 30.0% NSAIDs and 1.4% immunosuppres-
sant drugs. Furthermore, evidence of long-term use of
corticosteroids (Readcode 14P8.00) was found for 97.9% of
patients with PMR and/or GCA during follow-up. Diagnosis
with another autoimmune disease was recorded in 11.7% of
PMR/GCA patients and in 6.7% of non-PMR/GCA patients.
Mean systolic blood pressure was similar in individuals with and
without PMR/GCA but higher proportions of PMR/GCA
patients received blood pressure lowering medication in the year
before study entry (43.0% vs 36.7% in non-PMR/GCA patients).
The proportion of patients diagnosed with diabetes was higher
among individuals with GCA only (9.7% compared with 6.9%
in the PMR group and 6.2% in the non-PMR/GCA group).
Association between PMR/GCA and the 12 CVDs
During follow-up, 2272 (23.2%) patients with PMR only, 348
(29.9%) with GCA only, 167 (26.6%) with both conditions and
21 559 (20.4%) without either disease experienced one of the
12 CVDs. The incidence of fatal and non-fatal CVDs was slightly
lower in patients with than without PMR/GCA (adjusted
IRR=0.88, 95% CI 0.83 to 0.94; table 2 and ﬁgure 2). Patients
with PMR and/or GCA had lower incidence rates of unheralded
coronary death (IRR=0.79, 95% CI 0.66 to 0.95), and TIA
(IRR=0.67, 95% CI 0.54 to 0.84) than non-PMR/GCA patients
(see ﬁgure 3; online supplementary tables S6 and S7). No evi-
dence of association was found between PMR/GCA and any of
the other cardiac, cerebrovascular or vascular endpoints.
Additional adjustment for baseline medication, diagnosis of
other autoimmune diseases (see online supplementary ﬁgures S3
and S4) or year of entry (see online supplementary ﬁgure S5) did
not alter the estimates. No evidence of effect modiﬁcation by age
or sex was found (see online supplementary ﬁgures S6 and S7).
Lower incidence ratios were generally observed for patients
with incident than prevalent PMR/GCA (see ﬁgure 4 and online
supplementary table S7), and non-overlapping 95% CIs were
found for stable angina (IRR=0.76, 95% CI 0.64 to 0.90 vs
1.25, 95% CI 0.92 to 1.69), unheralded coronary death
(IRR=0.62, 95% CI 0.47 to 0.82 vs 1.09, 95% CI 0.85 to
1.42) and PAD (IRR=0.84, 95% CI 0.64 to 1.08 vs 1.69, 95%
Figure 1 Study ﬂow diagram.
CALIBER, CArdiovascular disease
research using LInked Bespoke studies
and Electronic health Records; CVD,
cardiovascular disease; GCA, giant cell
arteritis; PMR, polymyalgia rheumatica;
SID, supporting information for disease
diagnosis.
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CI 1.20 to 2.38). Among individuals with PMR/GCA, the
lowest rates of CVD were generally observed after 5 years of
disease duration (see online supplementary ﬁgure S8); with no
overlapping 95% CIs found for stable angina (adjusted
IRR=0.73, 95% CI 0.65 to 0.81 for 2–4 years; and IRR=0.43,
95% CI 0.30 to 0.62 for ≥5 years compared with ≤1 year
duration) and for heart failure (IRR=0.83, 95% CI 0.77 to
0.90 and IRR=0.61, 95% CI 0.49 to 0.76, respectively).
Incidence of CVD was higher in the GCA than in the pure
PMR group (70.60 vs 54.74/1000 person-years), greater differ-
ences being observed for heart failure, PAD and stable angina.
The small number of CVD events in the subgroup of patients
Table 1 Characteristics* of individuals with PMR, GCA and without either condition
Patients with PMR only (N=9776) Patients with GCA only (N=1164) Patients without PMR or GCA (N=105 504)
Sociodemographic factors
Age, years, median (IQR) 73 (65–79) 72 (64–79) 70 (62–77)
Women, n (%) 7042 (72.0) 845 (72.6) 76 286 (72.3)
Index of multiple deprivation, quintiles, n (%)
1 (least deprived) 1977 (20.3) 211 (18.2) 21 062 (20.0)
5 (most deprived) 1892 (19.4) 262 (22.6) 20 763 (19.8)
Ethnicity, n (%)
White 6683 (97.9) 844 (96.6) 62 766 (97.3)
Asian 77 (1.1) 14 (1.6) 768 (1.2)
Afro-Caribbean 21 (0.3) 6 (0.7) 448 (0.7)
Other 47 (0.7) 10 (1.1) 506 (0.8)
Duration of registration, years, median (IQR) 14.3 (6.7–26.9) 13.9 (6.4–26.1) 13.4 (6.0–25.3)
Consultation rate in previous year 10 (6–15) 10 (6–16) 5 (2–9)
Autoimmune diseases and inflammation
Other autoimmune disease, n (%) 1008 (10.3) 130 (11.2) 7116 (6.7)
Cardiovascular risk factors
Smoking, n (%)
Current 794 (9.0) 171 (16.6) 10 397 (11.4)
Former 2416 (27.3) 273 (26.5) 22 459 (24.6)
Never 5636 (63.7) 585 (56.9) 58 584 (64.1)
Diabetes 671 (6.9) 81 (9.7) 6526 (6.2)
Systolic blood pressure, mm Hg, mean (SD) 144 (18.4) 143 (19.7) 143 (19.0)
Body mass index, kg/m2, mean (SD) 26.9 (5.1) 26.8 (5.6) 26.7 (5.1)
Total cholesterol, mmol/L, mean (SD) 5.6 (1.2) 5.6 (1.2) 5.6 (1.1)
HDL cholesterol, mmol/L, mean (SD) 1.6 (0.5) 1.5 (0.5) 1.5 (0.5)
Serum creatinine, mg/L, mean (SD) 87.5 (24.3) 87.2 (21.8) 88.2 (24.3)
Medication use in previous year
Immunosuppressant drugs, n (%) 143 (1.5) – 593 (0.6)
Non-steroidal anti-inflammatory drugs, n (%) 3080 (31.5) 248 (21.3) 14 240 (13.5)
Oral corticosteroids, n (%) 4713 (48.2) 503 (43.2) 2476 (2.4)
Antiplatelet therapy, n (%) 843 (8.6) 123 (10.6) 8787 (8.3)
Blood pressure lowering medication, n (%) 4253 (43.5) 477 (41.0) 38 704 (36.7)
Statins, n (%) 978 (10.0) 102 (8.8) 9230 (8.8)
*Missing data (%): index of multiple deprivation, 0.4%; ethnic group, 37.9%; BMI, 41.8%; systolic blood pressure, 13.0%; smoking, 13.0%; total cholesterol, 61.2%; HDL cholesterol,
71.0%; serum creatinine, 47.6%.BMI, body mass index; GCA, giant cell arteritis; HDL, high-density lipoprotein; IRR, incidence rate ratio; PMR, polymyalgia rheumatica.
Table 2 Crude incidence rates of 12 CVDs with 95% CIs in individuals with and without PMR and GCA
Coronary and CVD death composite Fatal and non-fatal cardiovascular composite
No.
Events Rate per 1000 PY (95% CI)
No.
events Rate per 1000 PY (95% CI)
PMR only 1075 23.95 (22.56 to 25.43) 2457 54.74 (52.62 to 56.95)
GCA only 148 30.44 (25.91 to 35.76) 387 79.60 (72.05 to 87.94)
All GCA 216 25.32 (22.16 to 28.93) 555 65.06 (59.86 to 70.70)
PMR and/or GCA 1291 24.17 (22.89 to 25.52) 3012 56.39 (54.41 to 58.44)
Free of PMR and GCA 10 826 25.80 (25.32 to 26.29) 24 372 58.08 (57.36 to 58.82)
Notes: non-disease estimates are obtained in up to 10 randomly selected patients without PMR or GCA matched for sex, age, medical practice and index date; PY rates are unadjusted;
PMR and GCA estimates are obtained among patients diagnosed with these diseases who had supporting information for disease diagnosis. The coronary and CVD death composite
endpoint includes: stable angina, myocardial infarction, coronary heart diseases not otherwise specified and any cardiovascular death. The fatal and non-fatal CVD composite endpoint
additionally includes: transient ischaemic attack, peripheral arterial disease and non-fatal heart failure and ischaemic or haemorrhagic stroke.
CVD, cardiovascular disease; GCA, giant cell arteritis; PMR, polymyalgia rheumatica; PY, patient-years of follow-up.
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with GCA limited the power to examine differences in rate
ratios between patients with PMR and GCA for some CVDs.
However, no evidence of increased risk of CVD was observed
for those with a higher number of events (see online supplemen-
tary table S8) and for composites endpoints (ﬁgure 2).
Results from sensitivity analyses
Exclusion of individuals diagnosed with another autoimmune
disease or patients aged <50 years, inclusion of patients with
>6 months of follow-up and censoring of follow-up 2 years
before the diagnosis of PMR/GCA in patients who contributed
to both, PMR/GCA and non-PMR/GCA groups, did not alter
the results (see online supplementary table S8 and ﬁgure S10).
Patterns of association remained unchanged when PMR/GCA
individuals were included irrespective of whether disease
supporting information was recorded (see online supplementary
ﬁgure S11). Analyses comparing estimates before and after the
introduction of the pay-for-performance system of CPRD,
those of ﬁrst presentation of CVD (ie, regardless of other
earlier CVD presentations) and those restricted to patients with
evidence of active disease also showed similar patterns of asso-
ciations (see online supplementary ﬁgures S12 and S13 and
table S10).
DISCUSSION
This is to date the largest population-based longitudinal study
comparing the initial presentation of a wide range of symptom-
atic CVDs in patients with and without PMR and/or GCA
using contemporary data (1998–2010). The large sample size,
the longitudinal design and the information available allowed
examination of associations in individuals with prevalent and
incident PMR/GCA, pure and concomitant PMR and GCA,
different duration of disease and adjustment for sociodemo-
graphic and cardiovascular factors. In contrast to a previous
CALIBER study conducted in the same population in which
we reported increased rates of the initial presentation of
several CVDs in patients with rheumatoid disease (awaiting
publication), no evidence of increased risk of any of the
12 CVD presentations investigated was found in the presence
of PMR/GCA.
This study has several strengths. The longitudinal population-
based design provided evidence of temporality and enabled
investigation of associations with duration of PMR/GCA since
diagnosis. The large sample size allowed conducting separate
analyses for patients with incident and prevalent PMR/GCA and
pure and concomitant PMR and GCA, and investigation of sex
and age interactions. The time period covered (1997–2010) pro-
vided epidemiological evidence from a population diagnosed
and treated in recent years. The analysis of linked electronic
health records spanning primary, hospital and disease registry
data improved disease and cardiovascular endpoint ascertain-
ment,20 and allowed determination of outcomes independently
of PMR/GCA status and comparison with a non-disease random
sample drawn from the same population. Furthermore, the
matching strategy minimised the possibility of healthy study bias
related to healthcare service usage and the old age of the PMR/
GCA cohort.
Study limitations include the possibility of PMR/GCA mis-
classiﬁcation (eg, patients with atypical or mild disease might be
less likely to be diagnosed). In our study, PMR/GCA was deﬁned
based on recorded physician diagnosis in primary care and hos-
pitals. Information on American College of Rheumatology clas-
siﬁcation criteria or histology was not available in the dataset
for diagnosis conﬁrmation. However, to reduce the likelihood
of PMR/GCA misclassiﬁcation in patients >60 years of age with
incident seronegative rheumatoid arthritis or malignancies,21 the
primary analysis was restricted to patients who had supporting
information for diagnosis (eg, 24% of PMR/GCA patients had
diagnoses recorded in both primary and hospital care, and 98%
received prolonged corticosteroid therapy). Furthermore, the
majority of patients with PMR/GCA were women and the
median age was 73 years, all characteristics typical of patients
with PMR and/or GCA, and exclusion of patients with other
systemic diseases (eg, rheumatoid arthritis) did not affect the
estimates. Concerning PMR versus GCA diagnosis, 35% of
patients with GCA also had PMR and the number of patients
with PMR was eight times higher than that of those with GCA,
which is also consistent with previous reports.2 Furthermore,
adjustment for disease activity was not possible (baseline ESR
Figure 2 Adjusted incidence rate ratios for the association between
polymyalgia rheumatica and giant cell arteritis, and the initial
presentation of coronary disease and CVD. The coronary and CVD
death composite endpoint includes: stable angina, myocardial
infarction, coronary heart diseases not otherwise speciﬁed and any
cardiovascular death. The fatal and non-fatal CVD composite endpoint
additionally includes: transient ischaemic attack, peripheral arterial
disease, and non-fatal heart failure, ischaemic or haemorrhagic stroke.
CVD, cardiovascular disease; giant cell arteritis; IRR, incidence rate
ratios adjusted for index of multiple deprivation, smoking status,
systolic blood pressure, total and high-density lipoprotein cholesterol,
body mass index and diabetes; n, number of events; PMR, polymyalgia
rheumatic.
Figure 3 Adjusted incidence rate ratios for the association between
polymyalgia rheumatica and/or giant cell arteritis, and the initial
presentation of 12 cardiovascular diseases. Because of the small
number of events in speciﬁc clusters, estimates for unheralded coronary
death and intracerebral haemorrhage were not adjusted for body mass
index, systolic blood pressure, and total and high-density lipoprotein
cholesterol. IRR, incidence rate ratios adjusted for index of multiple
deprivation, smoking status, systolic blood pressure, total and
high-density lipoprotein cholesterol, body mass index and diabetes; n,
number of events.
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and CRP were available for 8% and 4% of non-PMR/GCA
patients, respectively); but analyses restricted to patients with
active PMR/GCA did not change the conclusions.
There are several possible explanations for the absence of
increased risk of CVD observed in patients with PMR/GCA
regardless of disease duration. PMR/GCA affects an old popula-
tion who might die before a detrimental effect of chronic sys-
temic inﬂammation on the arteries becomes symptomatic.9
Furthermore, the chronic use of corticosteroids (98% of PMR/
GCA patients in our cohort) might reduce the progression rate
of atherosclerosis through control of systemic inﬂammation.22
This is supported by our ﬁnding of decreasing ratios of most
types of CVDs among patients with longer disease duration.
Finally, unlike most previous studies that were conducted in ter-
tiary care centres, our cohort included all patients treated at
primary care and hospital level, making results more complete
and representative of the entire PMR/GCA population. Indeed,
PMR is primarily diagnosed and treated in primary care, and
studies conducted exclusively among patients managed at sec-
ondary or tertiary care levels are likely to include high propor-
tions of individuals with more severe disease or with atypical
presentation.7
Discordance with previous studies that found evidence of
increased risk of CVD in patients with PMR/GCA could be
related to their inclusion of patients with a history of CVDs
and/or primarily diagnosed and treated in tertiary health facil-
ities, and to better23 control of cardiovascular factors and early
start of anti-inﬂammatory medication, which could reduce and
control systemic inﬂammation24 25 as achieved in current clin-
ical practice for patients with chronic inﬂammatory conditions.
In our study, over 40% of patients with PMR/GCA received
blood pressure lowering medication, 10% statins and 9% anti-
platelet therapy.
In conclusion, regardless of disease duration, diagnosis of
pure or concomitant PMR and GCA was not associated with
increased risk of CVDs in a large, contemporary population-
based sample suggesting that, within the framework of current
clinical practice, these diseases do not represent an important
risk factor for CVD.
Key messages
What is already known on this subject?
The chronic inﬂammatory nature of polymyalgia rheumatica
(PMR) and giant cell arteritis (GCA) and the presence of clinical
or subclinical arteritis might lead to an increased risk of
cardiovascular diseases (CVDs). However, ﬁndings from the few
available studies investigating these associations are
heterogeneous and inconsistent.
What might this study add?
In this large, contemporary longitudinal population-based study
of patients treated at primary and hospital levels, we examined
the associations between prevalent and incident PMR/GCA
(PMR/GCA diagnosed before or after/on the date of study entry,
respectively) and pure (ie, diagnosis with PMR or GCA only) and
concomitant PMR and GCA, and the 12 most common clinical
presentations of CVDs. Regardless of PMR/GCA disease
duration, presence of pure or concomitant PMR and GCA was
not associated with an increased risk of CVD. No evidence of
interaction by sex or age was found.
How might this impact on clinical practice?
The study ﬁndings suggest that, under current clinical practice
targeted to patients with PMR and/or GCA, including early and
long-term administration of anti-inﬂammatory and
immunosuppressant drugs to control chronic systemic
inﬂammation associated with PMR/GCA, and management of
cardiovascular factors with primary prevention, cardiovascular
patient risk is similar to the risk of patients without PMR/GCA.
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